Is PCP a Stimulant, Depressant, or Something Else?

Phencyclidine, better known as PCP or “angel dust,” does not fit neatly into the stimulant or depressant category. It is classified as a dissociative anesthetic, a distinct drug class that can mimic stimulant effects at one dose, depressant effects at another, and hallucinogenic or psychosis-like states throughout. That pharmacological versatility is exactly what makes PCP so unpredictable and so poorly served by a one-word label.

Why PCP Resists a Single Category

Most recreational drugs slot comfortably into one box. Cocaine is a stimulant. Alcohol is a depressant. LSD is a hallucinogen. PCP borrows from all three categories without belonging to any of them. It shares some properties with depressant drugs, yet it is pharmacologically and therapeutically unique enough that researchers have long placed it in its own class alongside ketamine: the dissociative anesthetics.¹ Clinically, PCP acts primarily as a blocker of NMDA receptors, which are involved in excitatory signaling in the brain. But it also interacts with dopamine, norepinephrine, and serotonin systems, producing a cocktail of stimulant-like, sedative, and psychosis-mimicking effects that shift depending on dose, route, and the individual person.²

The drug was originally developed in the 1950s as a surgical anesthetic. It worked well at eliminating pain and consciousness, but patients waking up from PCP anesthesia often experienced severe agitation, hallucinations, and delirium. Those “emergence reactions” were so disturbing that PCP was pulled from human medical use by the late 1960s. It subsequently migrated to the street, where its unpredictable blend of effects became both its draw and its danger.

The Stimulant Side of PCP

If you only looked at someone’s vital signs during mild PCP intoxication, you might reasonably guess they had taken a stimulant. Blood pressure climbs, heart rate increases, and pupils dilate. These sympathomimetic effects arise because PCP blocks the reuptake of dopamine and norepinephrine, allowing those chemicals to build up in the synapses. The result is cardiovascular and central nervous system activation that looks, on a monitor, a lot like what cocaine or amphetamines produce.²

PCP also boosts extracellular dopamine and serotonin in the brain’s reward pathway, specifically in a region called the nucleus accumbens.³ That dopamine surge likely accounts for the euphoria some users report at lower doses, and it also helps explain why PCP can be habit-forming. The stimulant profile is real, but it is only one piece of the puzzle.

The Depressant and Anesthetic Side

PCP was invented to knock people out for surgery, and it has not lost that capacity. At higher doses, the drug produces profound sedation, loss of coordination, and a state of dissociated numbness. Users may become unresponsive, lose the ability to speak coherently, or slip into a catatonic-like condition. The numbness and light-headedness reported during intoxication, along with vertigo, ataxia, and involuntary eye movements known as nystagmus, reflect PCP’s roots as an anesthetic agent.⁴ In emergency rooms, the clinical signs of PCP intoxication are often described in three dose-related stages, though patients can wax and wane unpredictably between them.⁵

This dual personality is the core reason PCP does not fit into a tidy box. At low doses, sympathomimetic activation predominates: the user feels alert, energized, maybe euphoric. As the dose increases, the anesthetic qualities take over: coordination crumbles, the body goes numb, and consciousness may slip away entirely. Both profiles exist in the same molecule, separated mainly by how much someone takes and how fast it hits the brain.

The Psychosis-Mimicking Dimension

What truly sets PCP apart from both stimulants and depressants is its ability to produce a mental state that closely resembles schizophrenia. Other drugs can cause psychotic symptoms. Amphetamines, for instance, can trigger paranoia and hallucinations. But PCP psychosis is distinctive because it mirrors both the “positive” symptoms of schizophrenia, such as hallucinations and paranoid delusions, and the “negative” symptoms, like emotional withdrawal and reduced movement. It also reproduces the formal thought disorder and specific cognitive deficits seen in schizophrenia, something amphetamines do not do.⁶

This observation has been so consistent that researchers have used PCP as a pharmacological model for schizophrenia, helping probe the role of NMDA receptors in psychotic illness. For the person experiencing PCP-induced psychosis, though, the clinical details are secondary to the reality: this is a drug that can temporarily disconnect you from the world in a way that feels frighteningly similar to a serious psychiatric disorder. Episodes may last hours or, in heavy users, persist for days or weeks after the drug itself has been metabolized.

How NMDA Receptor Blockade Drives These Effects

The unifying mechanism behind PCP’s strange blend of properties is its action at the NMDA receptor, a type of glutamate receptor involved in excitatory brain signaling, learning, and sensory processing. PCP physically enters the receptor’s ion channel and plugs it, preventing calcium and sodium from flowing through. This is called uncompetitive or open-channel blockade because the drug can only enter the channel after it has been activated by glutamate.⁷ Once PCP lodges in the channel, it dissociates slowly, which is part of why its effects last so long compared to shorter-acting blockers.

Structural studies have visualized how PCP, ketamine, and the Alzheimer’s drug memantine each sit inside the NMDA receptor channel. Although all three block the same channel, they form different patterns of contact with the pore-lining residues. Those differences mostly control how quickly each drug leaves the receptor, rather than how fast it gets in.⁸ PCP’s particularly slow departure from the channel helps explain why its effects are prolonged and why intoxication can wax and wane as the drug gradually works its way off the receptor and then reattaches.

But PCP does not limit itself to NMDA receptors. It also binds to sigma receptors in the brain, and through that interaction it can modulate dopamine release in the brain’s reward center.⁹ This multi-target pharmacology is what gives PCP its stimulant-like cardiovascular effects, its depressant and anesthetic qualities, and its psychotomimetic properties all at once. Calling it “just” a stimulant or “just” a depressant captures about a third of the story.

What PCP Intoxication Actually Looks Like in an Emergency Room

The stereotypical image of PCP intoxication involves a wildly agitated person impervious to pain, but the clinical reality is more variable. In a case series of 184 PCP-positive patients, roughly two-thirds had horizontal nystagmus (involuntary side-to-side eye movements), about half had vertical nystagmus, just under half had high blood pressure, about 39% were agitated, and a quarter had retrograde amnesia.¹⁰ In a much larger review of 1,000 cases, nystagmus and hypertension together appeared in only about 57% of patients, and many had neither.¹¹

That means a significant number of PCP-intoxicated people present without the “classic” signs. Some are sedated and withdrawn rather than agitated. Some are confused but calm. Others are fully combative. The dose-related staging described in emergency medicine literature acknowledges this range: low-dose intoxication tends toward euphoria, nystagmus, and mild confusion; moderate doses bring more pronounced numbness, ataxia, and agitation; and high doses can produce seizures, coma, or respiratory depression. But patients move unpredictably between these stages, which is what makes PCP such a headache for emergency clinicians.

Some users become irritable, argumentative, or hostile, especially under social stress or when asked to perform demanding tasks.⁴ Combined with diminished pain perception, this irritability feeds the perception that PCP users are dangerously violent. And while violence does occur, it is far from universal. Many users are simply confused, disconnected, or sedated.

The “Superhuman Strength” Myth

Few drugs carry as much urban legend as PCP. Stories of users shrugging off tasers, breaking handcuffs, or fighting off half a dozen police officers have been circulating since the 1970s. The pharmacological grain of truth is that PCP profoundly dulls pain perception while simultaneously raising blood pressure and heart rate, so an intoxicated person may continue exerting themselves past the point where pain would normally force them to stop. But the idea of actual superhuman strength, muscles suddenly capable of more force than they could normally generate, is a myth. PCP does not increase muscular strength. What it does is remove the feedback that keeps people from injuring themselves.²

This myth has real consequences. Encounters between law enforcement and people suspected of PCP use have historically escalated quickly, sometimes with fatal results, partly because of exaggerated expectations about what the drug does. The clinical profile does include bizarre and unpredictable behavior in some patients, and that unpredictability warrants caution. But “unpredictable” is not the same as “superpowered,” and conflating the two has led to disproportionate use of force in situations that might have been managed with de-escalation.

How PCP Compares to Ketamine

PCP and ketamine are both dissociative anesthetics that block NMDA receptors, and they are often discussed together. But their clinical profiles diverge in important ways. Ketamine is roughly one-tenth as potent as PCP in behavioral assays, meaning you need a much larger dose of ketamine to produce the same degree of disruption. PCP’s effects are also slower to kick in but much longer-lasting.¹² A ketamine experience at recreational doses might last 45 minutes to an hour; PCP intoxication can last for many hours and sometimes lingers for days.

The difference is not just one of dose and duration. Ketamine generally produces deeper central nervous system depression than PCP at comparable levels of NMDA blockade. Research has shown that ketamine, but not PCP, acts on a specific type of GABA receptor found in the cerebellum, the brain region that coordinates movement. This extra mechanism may explain why ketamine has a lower incidence of the agitation and psychotic emergence reactions that made PCP unsuitable for human medicine.¹³ Ketamine has remained in clinical use as an anesthetic and, more recently, as a treatment for depression. PCP has not.

Neurotoxicity Concerns

Beyond the immediate dangers of intoxication, there is evidence that NMDA receptor blockers, including PCP, can damage neurons. In animal studies, PCP and related drugs cause morphological damage to neurons in the cerebral cortex.¹⁴ This is an ironic twist: NMDA blockers can actually protect the brain during events like stroke, where excessive glutamate signaling kills neurons. But when used on a healthy brain, those same drugs can trigger a different kind of injury, likely because blocking NMDA receptors disrupts the normal balance of excitatory and inhibitory signaling and causes certain circuits to become overactive in compensation.

For people who use PCP repeatedly, this neurotoxic potential is a serious concern. Chronic users often report persistent cognitive problems, including trouble with memory, attention, and executive function, that can outlast the drug itself by months. Whether those deficits are fully reversible remains an open question, and the difficulty of studying chronic PCP users in controlled settings means the long-term data are limited.

Synthetic PCP Analogues

PCP itself has waned from its peak of popularity in the 1970s and 1980s, but a growing number of synthetic analogues have appeared through online drug markets. Compounds like 4-MeO-PCP and 3-MeO-PCMo are structurally tweaked versions of phencyclidine that retain the dissociative effects while varying in potency, duration, and side-effect profiles.¹⁵ These drugs activate the same dopamine-driven reward pathways as PCP, which means they carry similar risks of compulsive use. Because they are newer and less studied, the margin between a “recreational” dose and a dangerous one is even less well understood than it is for PCP itself.

Standard drug tests may not detect these analogues, and emergency physicians encountering someone on a novel PCP derivative may have few clinical guidelines to draw from. The symptoms tend to follow the same general pattern as PCP intoxication, including nystagmus, agitation, numbness, and cardiovascular activation, but the unpredictable potency of underground chemistry means that overdoses can occur at doses the user did not expect to be dangerous.

Why the “Stimulant or Depressant” Framework Breaks Down

The stimulant-depressant-hallucinogen classification system that most people learn in health class works reasonably well for many common drugs, but it was never designed to handle a compound like PCP. That three-category model sorts drugs by their most prominent behavioral effect: uppers speed you up, downers slow you down, and hallucinogens alter perception. PCP does all three in sequence or simultaneously, depending on dose and context. Trying to force it into one of those boxes misses the point and can lead to dangerous misunderstandings about what to expect from it.

The dissociative anesthetic label, while less intuitive, captures the drug’s character much more accurately. “Dissociative” refers to the psychological disconnection from the body and environment that users experience: feeling detached from their own limbs, losing the ability to judge distance or time, or becoming unresponsive to pain. “Anesthetic” acknowledges the drug’s medical origin and its capacity to suppress sensation and consciousness at sufficient doses. Together, the two words describe a drug that does not excite or depress the brain so much as it scrambles the integration of sensory and cognitive processing, producing a disorganized state that borrows selectively from stimulant, depressant, and psychotomimetic territory without settling in any of them.